Our solutions are straight forward formulations that have been developed with the help of industry leading scientists at McMaster University and in our own labs. They offer a radical degree of temperature stabilization that has been shown to stabilize vaccines that normally require -80°C storage to be stored as high as 40°C.
Our technology platforms have also been shown to be applicable to a wide array of bio-therapeutics beyond vaccines. Small molecules, enzymes, biologics, DNA, RNA and mRNA-LNPs can all be stabilized.
Extend long term stability at any temperature. Our solution can extend the stability of vaccines and biologics at refrigerator or freezer temperatures, which can be the difference between getting a product to market or shelving it.
Formulate in a film, powder, porous sugar glass or solution. Our technology platforms offer a variety of options for formulation and delivery forms for your therapeutic product.
Dr. Filipe’s lab at McMaster University started experimenting with stabilizing vaccines and biologics in pullulan in 2014. This breakthrough work evolved to include trehalose and has resulted in numerous publications and patents. In 2019, Elarex Inc. was co-founded by Robert DeWitte and Carlos Filipe to bring this proprietary technology to market in the form of PT120-D. Since then, we have developed XE120-L, a second technology platform specifically for stabilizing mRNA-LNPs in liquid.
The XE120-L platform is an innovation from the newly formed labs of Elarex Inc. During the course of the pandemic, it has become clear that mRNA-LNP vaccines represent a new frontier of genomic medicine but are limited by their extreme dependence on the cold chain. Our XE120-L platform enables the stabilization of mRNA-LNPs in liquid, without specialized lipids or mRNA.
The excipients used in the technology are all approved for parenteral administration by the U.S. FDA, and the process to create the LNPs is straightforward and simple.
This dried technology platform is a straightforward, patented formulation that has been developed over the past five years at McMaster University. It offers exceptional temperature stabilization that has been shown to stabilize vaccines that normally require -80°C storage to be stored at 40°C, a difference of 120 degrees. In vivo data in mice has shown that this stabilization results in effective vaccines when stored at the higher temperature. No freeze drying is necessary, and the process is simple, with all the components of the solution on the FDA “GRAS” list (Generally Regarded as Safe). This differs from all the other competitors’ offerings in this field.
This technology has also been shown to be applicable to a wide array of bio-therapeutics beyond vaccines. Small molecules, enzymes, biologics, DNA and RNA have all been shown to benefit from the stabilization offered by this technology.
McMaster University has backed Elarex with financial and in-kind contributions. Having been recently named Canada’s top research-intensive university, McMaster is the perfect partner for a startup in need of research expertise and facilities that would be hard to access otherwise.
“Getting our research into the hands of those who can put it to its best use is critical for us. Elarex has been a great partner in bringing investors and business expertise to help move Dr. Filipe’s technology from lab to market. Together we have the potential to make an impact in the fight against COVID-19 and other infectious diseases.” — Karen Mossman, vice-president, research, and leading virologist, McMaster University